Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer

Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer

Background: Neoadjuvant chemotherapy (NACT) with human epidermal growth factor receptor 2 (HER2) blockade is the preferred approach for treating early and locally advanced HER2-positive breast cancer. There is a lack of robust data comparing pathological complete response (pCR) and survival outcomes...

Full description

Bibliographic Details
Main Authors: Anshul Gupta, Ajay Gogia, SVS Deo, DN Sharma, Sandip Mathur, Hari Krishna Raju Sagiraju
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Anthracyclines
Trastuzumab
Neoadjuvant chemotherapy
HER2-positive breast cancer
pCR
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294223000631

Internet

http://www.sciencedirect.com/science/article/pii/S2468294223000631

Similar Items